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In recent years, advanced radiation therapy techniques, including stereotactic body
radiotherapy and carbon–ion radiotherapy, have progressed to such an extent that
certain types of cancer can be treated with radiotherapy alone. The therapeutic
outcomes are particularly promising for early stage lung cancer, with results matching
those of surgical resection. Nevertheless, patients may still experience local tumor
recurrence, which might be exacerbated by the acquisition of radioresistance after
primary radiotherapy. Notwithstanding the risk of tumors acquiring radioresistance,
secondary radiotherapy is increasingly used to treat recurrent tumors. In this context,
it appears essential to comprehend the radiobiological effects of repeated photon and
particle irradiation and their underlying cellular and molecular mechanisms in order to
achieve the most favorable therapeutic outcome. However, to date, the mechanisms
of acquisition of radioresistance in cancer cells have mainly been studied after
repeated in vitro X-ray irradiation. By contrast, other critical aspects of radioresistance
remain mostly unexplored, including the response to carbon-ion irradiation of X-ray
radioresistant cancer cells, the mechanisms of acquisition of carbon-ion resistance,
and the consequences of repeated in vivo X-ray or carbon-ion irradiation. In this
review, we discuss the underlying mechanisms of acquisition of X-ray and carbon-ion
resistance in cancer cells, as well as the phenotypic differences between X-ray and
carbon-ion-resistant cancer cells, the biological implications of repeated in vivo X-ray
or carbon-ion irradiation, and the main open questions in the field.
Keywords: cancer, radioresistance, acquisition, X-ray radiation, carbon-ion radiation, repeated irradiation, DNA
repair, aggressiveness
INTRODUCTION
The previous decade has seen significant developments in the techniques used in radiotherapy,
and advanced radiotherapy has become increasingly adopted. Among advanced radiotherapy
techniques, stereotactic body radiation therapy (SBRT) relies on a small irradiation field to precisely
deliver high doses of radiation, typically above 10Gy per fraction, to local tumors. SBRT has been
applied to the treatment of various cancers, including lung (1), liver (2), and prostate cancer (3).
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The therapeutic outcomes of SBRT are particularly promising
for early stage lung cancers, with local control rates exceeding
80% (1, 4) and clinical outcomes comparable to those of surgical
resection (5, 6).
In addition to SBRT, particle-beam therapy, such as carbon-
ion (C-ion) radiotherapy (CIRT), has demonstrated excellent
therapeutic outcomes in various types of cancer (7). CIRT
has both physical and biological advantages compared with X-
ray therapy. With CIRT, tumors are irradiated with C-ions of
relativistic energy, which means that C-ions penetrate the body
with lower ionization that significantly increases toward the
end of the beam path. This radiophysical feature is commonly
referred to as the “Bragg-peak” and contributes to increasing
the radiation dose delivered to the tumor while minimizing
the radiation dose delivered to the skin and surrounding
healthy tissues. Furthermore, CIRT has a relative biological
effectiveness, which is defined as the ratio of a dose of radiation
to the dose of X-ray radiation producing the same biological
effects that is >2. Another important feature of CIRT is its
effectiveness against conventional X-ray radiotherapy resistant
cancers, including melanoma (8) and bone and soft-tissue
sarcoma (9–11). Furthermore, CIRT reportedly works as an
alternative ablative treatment for early stage lung cancer, in
particular for elderly and inoperable patients (12).
Nevertheless, recent studies show that local recurrence
can still occur after advanced radiotherapy. For example, an
incidence of local recurrence ranging from 4.9 to 19% in patients
who received SBRT for lung cancer treatment was reportedly
dependent on treatment regimen, tumor stage, and follow-up
periods (13–18). Furthermore, 23.3% of patients who received
CIRT for the treatment of stage I non-small cell lung cancer also
exhibited local recurrence (19).
In cases of tumor recurrence after primary radiotherapy,
patients can rarely be treated again with the same radiation
regimen, because the tumor might acquire radioresistance, and
it is possible that healthy surrounding tissues will not tolerate
additional irradiation. Nevertheless, recent studies report that
SBRT and CIRT can be used for re-irradiation of recurrent
tumors, taking into account both the dose tolerance of healthy
tissues and location of the recurrent tumor (20–23). However,
several issues related to re-irradiation with SBRT or CIRT still
need to be considered. First, only a few studies have reported
the clinical outcomes of repeated irradiation, and second, the
characteristics of recurrent tumor after primary radiotherapy
are largely unknown. In this review, we focus on the biological
aspects of acquired X-ray and C-ion resistance in cancer cells and
discuss the differences between the consequences of in vitro and
in vivo repeated irradiation, the possible mechanisms of acquired
resistance in cancer cells, and issues that must be addressed in
this research field.
ACQUISITION OF PHOTON
RADIORESISTANCE IN VITRO
Radioresistance acquisition in cancer cells and its underlying
mechanisms have been mainly studied using radioresistant cell
lines established through repeated in vitro photon (e.g., X-ray
or γ-ray) irradiation. Because conventional radiotherapy usually
relies on a total dose of ∼60Gy applied in 2-Gy fractions, many
studies adopted similar radiation regimens in order to establish
radioresistant cell lines (Table 1) (24–41). Importantly, most of
these studies showed that the survival of repeatedly irradiated
cells was significantly higher than that of the parental cells,
which indicated that in vitro, various cell lines could acquire
radioresistance following multiple rounds of X-ray irradiation.
Cellular Processes Involved in the
Acquisition of Radioresistance Following
Repeated Photon Irradiation
The mechanisms of acquisition of radioresistance in cancer
cells have been associated with a variety of biological
processes (Table 1). However, in many cases, the acquisition of
radioresistance can be reasonably explained by the induction
of epithelial-to-mesenchymal transition (EMT), which is
defined as phenotypic and molecular alterations that result
in the loss of epithelial-cell characteristics and the gain of
mesenchymal-cell characteristics. As cancer cells undergo EMT,
epithelial markers, such as E-cadherin, ZO-1, and cytokeratin,
are downregulated, whereas mesenchymal markers, such as
N-cadherin, vimentin, snail, and twist, are upregulated, and in
some cases, morphological changes lead to the appearance of
spindle-shaped cells (42). The most prominent characteristics
acquired by cancer cells after EMT are migratory and invasive
properties, conferring them a significant metastatic potential,
and resistance to chemotherapeutic drugs and ionizing radiation.
Indeed, several studies report that EMT in cancer cells, which
was defined by reduced E-cadherin protein levels, increased N-
cadherin protein levels, and enhanced migration potential, could
be induced by single X-ray irradiation (43, 44). Furthermore,
Shintani et al. (39) showed that repeated X-ray irradiation of
A549 cells (2Gy weekly for >6 months) induced significant
radioresistance and typical EMT (i.e., decreased E-cadherin and
increased N-cadherin mRNA and protein levels). Collectively,
these data support the notion that EMT induction following
X-ray irradiation is a contributing factor in the acquisition
of radioresistance.
Another factor involved in the acquisition of radioresistance
following repeated X-ray irradiation is an enrichment in cancer
stem cells (CSCs), which are known to exhibit higher DNA-
repair potential (45) and resistance to reactive oxygen species-
induced cytotoxicity (46, 47). CSCs are also often found
to be in the G0 phase (48), a quiescent state outside the
normal cell cycle and associated with reduced cell proliferation.
All of these characteristics are recognized for their role in
cellular radioresistance. Additionally, CSCs are important in
radioresistance acquisition because of their impact on the
heterogeneity of the cell population within a tumor. Indeed, in
the hierarchy model, CSCs produce a more differentiated non-
CSC progeny exhibiting significant cell-proliferation potential
but lacking stem cell properties. Notwithstanding their reduced
proliferation rate as compared with their non-CSC progeny,
CSCs can self-renew, and maintaining their stemness. Notably,
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TABLE 1 | Repeated photon irradiation regimen for the establishment of radioresistant cancer cells.
Author (year) Single dose
(Gy)
Total dose
(Gy)
Regimen Parental cell
line
Main findings References
Kuwahara et al. (2009, 2011) 0.5 >1,600 2Gy of α-ray, 0.5
Gy/12 h
HepG2 • Promoted DNA repair
• Decreased autophagic cell death
(24, 25)
Lee et al. (2010) 2 80 Over 5 months H460 • Decreased reactive oxygen species
production
• TP53I3 downregulation
(26)
Lin et al. (2010) 2 60 (*1) OECM1
KB
SAS
• GP96 upregulation (27)
Luo et al. (2017) 2 30 (*1) TE-1
Eca-109
• Concomitant increase in CDDP
resistance
(28)
Lynam-Lennon et al. (2010) 2 50 (*1) OE33 • Promoted DNA repair (29)
Mitsuhashi et al. (1996) 6.37 63.7 (*1) NMT-1 • (*2) (30)
Pearce et al. (2001) 2–4 40–60 Weekly MDA-MB-231 • (*2) (31)
Post et al. (2018) 1–4 64 4 Gy/2 weeks, 4
times/week
MCF7 • (*2) (32)
Russell et al. (1995) 2 50 Every 5–7 days IMR32 • Promoted DNA repair (33)
Sato et al. (2014, 2017) 10, 5 (*3) 60, 30 (*3) Every 2 weeks NR-S1 • Promoted DNA repair
• Resistance to C-ion radiation
• Increased phosphorylation of mTOR
(34, 35)
Shimura et al. (2010, 2014, 2017) 0.5 31–62 Every 12–24 h Hela
HepG2
• Activation of the DNA-PK-Akt-Cyclin D1
pathway
(36–38)
Shintani et al. (2011) 2 60 Over 6 months A549 • Induction of epithelial to mesenchymal
transition
(39)
You et al. (2014) 2 80 40 times over 5
months
A549
H157
H358
• Increased phosphorylation of JAK2 and
STAT3
• Increased levels of Bcl2 and Bcl2-XL
(40)
Zhou et al. (2010) 6.37 76.44 12 times over 6
months
Hep2 • Increased fraction of cells in the G0
phase
• Increased telomerase activity
(41)
(*1) There is no description about treatment regimen.
(*2) There is no significant finding other than radioresistance acquisition.
(*3) 5Gy and 30Gy of single and total dose is that of C-ion irradiation.
the non-CSC population displays higher radiosensitivity than the
CSC population. Consequently, radiation treatment can increase
the relative abundance of CSCs in the tumor, which promotes
asymmetric cell proliferation and, therefore, an enrichment
in CSCs.
Lagadec et al. (49) reported enrichment in CD44high/CD24low
breast CSCs following repeated X-ray irradiation of human breast
cancer MCF7 and T47D cells, with irradiated cells displaying
increased sphere-formation potential. Furthermore, they found
that repeated irradiations led CSCs in the G0 phase to reenter
the cell cycle, thereby promoting their proliferation, whereas
the non-CSC population underwent apoptosis according to the
increased fraction of cells in the sub-G1 phase (49). Additionally,
Ghisolfi et al. (50) showed that single X-ray irradiation of cancer
cells with a dose of 2Gy to 10Gy increased the expression of
the pluripotency markers OCT3/4 and SOX2 and promoted the
enrichment of a CSC subpopulation. Moreover, Mani et al. (51)
established a link between EMT and CSCs by demonstrating
that TGF-β-induced EMT generated a subpopulation with
CSC properties, including characteristic CSC markers, such as
CD44high/CD24low and elevated sphere- and mammosphere-
formation potential.
To the best of our knowledge, a definitive mechanism
responsible for the induction of CSCs remains unclear; however,
DNA damage or chromosomal aberration can enhance CSC
induction along with increased oncogene activity. Liang et al.
(52) showed that DNA damage from UV irradiation and
the chromosomal aberrations induced by Mad2 overexpression
also increased by Myc and SOX2 expression in human
nasopharyngeal carcinoma CNE cell lines and promoted cell dye-
exclusion, colony formation, and sphere-formation capacities.
These data suggest that the accumulation of DNA damage
by repeated X-ray irradiation induces not only EMT but also
enrichment of CSCs with increasing oncogenic activity, whereas
secondary induction of a CSC subpopulation by EMT (known
as cancer plasticity) further contributes to the development
of radioresistance.
Molecular Processes Involved in the
Acquisition of Radioresistance Following
Repeated Photon Irradiation
We and others have independently reported that repeated X-ray
irradiation can result in enhanced DNA-repair capacity (24, 29,
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33, 34). In our study, the mouse squamous cell carcinoma NR-
S1 cell line was irradiated with a total dose of 60Gy of X-ray
radiation applied in 10-Gy fractions in order to establish the X60
radioresistant cancer cell line (Figure 1). Notably, the D10 value
(i.e., the radiation dose required to decrease the survival to 10%
of the non-irradiated condition) and cell survival after 10Gy of
X-ray radiation were 1.6- and 3.8-fold higher, respectively, for
X60 cells than for parental NR-S1 cells (34). Furthermore, 24 h
after exposure to 10Gy X-ray radiation, the number of S139
phosphorylated-H2AX (γ-H2AX) foci, a marker of DNA double-
strand breaks (DSBs), was 2.5-fold lower in X60 cells than in
NR-S1 cells, indicating that DSBs were repaired more efficiently
in X60 cells than in NR-S1 cells (34). Indeed, the collected results
of numerous studies (Table 1) further demonstrate that enhanced
DNA-repair capacity is a common feature of radioresistant
cancer cells arising from repeated X-ray irradiation.
As part of the investigation of the molecular mechanisms
underlying the acquisition of radioresistance, several groups
have highlighted a relationship between DNA repair and pro-
survival signaling pathways, such as the Akt and mechanistic
target of rapamycin (mTOR) pathways. Shimura et al. (36)
suggested a potential molecular mechanism for the acquisition of
radioresistance induced by repeated X-ray irradiation, showing
that cyclin D1 expression and Akt phosphorylation levels were
increased in X-ray-resistant derivatives of HeLa and HepG2 cells
established following repeated irradiation. These radioresistant
cancer cell lines also displayed constitutively elevated levels of
DSBs, as measured by H2AX and ataxia telangiectasia mutated
(ATM) phosphorylation, relative to those in parental cell lines.
Strikingly, downregulation of cyclin D1 in radioresistant HeLa
and HepG2 derivatives decreased H2AX-, ATM-, and Akt-
phosphorylation levels, as well as cell survival, after further X-
ray irradiation. Therefore, they proposed that repeated X-ray
irradiation triggered cyclin D1 overexpression and forced cell
cycle progression, which in turn caused further DNA damage
and led to the activation of both Akt signaling and DNA-
dependent protein kinase activity, a central component in the
non-homologous end joining DSB-repair pathway. Eventually,
these signals promoted further cyclin D1 overexpression as part
of a positive-feedback loop that likely resulted in the acquisition
of radioresistance (36, 38, 53, 54).
In addition to Akt signaling, mTOR signaling has been
associated with the acquisition of X-ray resistance in cancer
cells. Chang et al. (55) established radioresistant derivatives
of PC-3, DU145, and LNCaP cells following repeated X-
ray irradiation with a dose of 2 Gy/day for 5 consecutive
days (55) and showed that these radioresistant cancer cell
lines exhibited both mesenchymal and CSC phenotypic traits.
Interestingly, they found that radioresistant cells treated with
BEZ235, a specific inhibitor of the phosphoinositide 3 (PI3) and
mTOR kinases, displayed decreased expression of mesenchymal
(N-cadherin, vimentin, and snail) and CSC (OCT3/4, SOX2,
and CD44) markers, increased expression of the epithelial
marker E-cadherin, and reduced cell survival. They further
showed that BEZ235, the PI3-kinase inhibitor BKM120, and the
mTOR-kinase inhibitor rapamycin, suppressed the expression
FIGURE 1 | Diagram describing the establishment of radioresistant cancer cells through repeated X-ray or C-ion irradiation. Mouse squamous cell carcinoma NR-S1
cells were irradiated six times at 2-week intervals with 10Gy of X-ray radiation (left) or 5Gy of C-ion radiation (left). The radioresistant derivative cell lines exposed to
total doses of 60Gy of X-ray radiation and 30Gy of C-ion radiation were denoted as X60 and C30 cells, respectively (34, 35).
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of DNA-repair proteins induced by X-ray irradiation, including
Ku80, BCRA1, and BRCA2 (56). Moreover, we independently
demonstrated that mTOR signaling was enhanced in X60
radioresistant cancer cells as compared with parental NR-S1
cells, whereas rapamycin treatment decreased their radioresistant
phenotype (35). Importantly, rapamycin also suppresses both
non-homologous end joining and homologous recombination
(HR) DSB-repair pathways (57). Collectively, these results
indicate that activation of the pro-survival Akt and mTOR
signaling pathways can eventually increase the DNA-repair
capacity of repeatedly irradiated cancer cells and thereby
promote the acquisition of radioresistance.
ACQUISITION OF C-ion
RADIORESISTANCE IN VITRO
Acquisition of C-Ion Resistance Following
Repeated X-Ray Irradiation
In clinical practice, CIRT is an effective treatment for locally
recurrent tumors after primary radiotherapy, likely because cell
killing by C-ion radiation is independent of various cellular or
tumor characteristics, including p53 status (58), cell cycle phase
(59, 60), and hypoxia (61–63). Although these findings suggest
that C-ion radiation should be effective against radioresistant
cancer cells arising from repeated X-ray irradiation, no available
experimental data supported this hypothesis. Therefore, in a
recent study, we determined whether C-ion radiation could
efficiently kill X60 radioresistant cancer cells. Contrary to our
expectations, we found that compared with parental NR-S1 cells,
X60 cells exhibited significant levels of resistance against C-ion
radiation (34). Furthermore, 24 h after C-ion irradiation, the
number of γ-H2AX foci was 2.5-fold lower in X60 cells than in
NR-S1 cells. These observations indicated that repeated X-ray
irradiation of cancer cells with a relatively high dose of 10Gy
per fraction could induce not only X-ray resistance but also C-
ion resistance (34). We believe that further investigations using
such radioresistant cells will likely lead to the discovery of novel
mechanisms contributing to C-ion resistance in cancer cells.
To gain further insight into the underlying mechanisms of
radioresistance in X60 cells, in a recent study, we compared
several biological and morphological traits of X60 cells and
parental NR-S1 cells, including cell shape and size, number of
heterochromatin domains in the nucleus, and DNA content
(34). Additionally, we analyzed the correlation between these
factors and X-ray or C-ion resistance. Interestingly, we found
that the number of heterochromatin domains was strongly
correlated with both X-ray and C-ion resistance, which
suggested that heterochromatin components or the dynamics
of heterochromatin were also involved in the acquisition
of radioresistance.
Indeed, previous studies show that heterochromatin proteins,
such as HP1α (64) and CAF1 (65), are directly involved in
DNA repair, and recent studies report that DNA damage
in heterochromatin domains is mainly repaired by the HR
machinery (66, 67). The damaged heterochromatin first move
to the periphery of the heterochromatin domain to prevent
abnormal recombination or deleterious expansion at satellite
or repetitive DNA sequences, after which Rad51, the core
component of the HR machinery, accumulates at DNA-damage
sites located at the periphery of the heterochromatin domain
(66, 67). Although these studies were conducted in Drosophila
and yeast cells, Jakob et al. (68) observed similar dynamics of
damaged heterochromatin and DNA-repair following heavy ion-
beam irradiation of mammalian cells, finding that immediately
after irradiation, DSBs were formed in the heterochromatin
along the uranium ion-beam track. Within 30min, the DSB sites
relocated to the periphery of the heterochromatin domain, and
replication protein A, a marker of DNA-end resection during HR
repair, accumulated at these DSB sites (68). In agreement with
these findings, our preliminary results showed that 1 h after X-
ray or C-ion irradiation, X60 cells displayed an increased number
of Rad51 foci as compared with NR-S1 cells (Figure 2). Because
Rad51 is a central factor in the HR machinery, Rad51 foci are
commonly considered to represent sites of ongoing DSB repair
by HR.
Furthermore, several studies report that HR repair can
remove complex DNA lesions, including clustered DNA damage
(69) and DNA-protein crosslinks (70, 71). Given that X60
cells exhibit increased numbers of heterochromatin domains
and radiation-induced Rad51 foci as compared with NR-S1
cells (Figure 2), it appears conceivable that enhanced HR-
repair capacity and heterochromatin dynamics contribute to
X-ray and C-ion resistance in X60 cells. Whether such a
mechanism of acquisition of radioresistance could be specific
to X60 cells or shared by other radioresistant cancer cell lines
remains to be explored. Nevertheless, future studies focusing
on further our understanding of the underlying mechanisms
of DSB repair in heterochromatin domains could, therefore,
represent a significant breakthrough toward elucidating the
mechanisms of acquisition of radioresistance in cancer cells
and identifying novel therapeutic strategies for the treatment of
radioresistant tumors.
Acquisition of C-Ion Resistance Following
Repeated C-Ion Irradiation
To date, only a limited number of studies have investigated the
acquisition of C-ion resistance, and it remains unclear whether
repeated C-ion irradiation can lead to radioresistance in cancer
cells. To address this question, in a recent study, we irradiated
NR-S1 cells with a total dose of 30Gy of C-ion radiation applied
in 5-Gy fractions in order to establish a C30 radioresistant cancer
cell line (Figure 1). This C-ion irradiation regimen is biologically
equivalent to the X-ray irradiation regimen used to establish the
X60 cell line, because NR-S1 cells exhibit comparable survival
following exposure to 5Gy and 10Gy of C-ion and X-ray
radiation, respectively. Interestingly, when we assessed the X-
ray and C-ion radiation sensitivity of C30 cells using a colony
formation assay, we found that C30 cells displayed moderate
resistance to C-ion radiation but not to X-ray radiation (35).
Although it remains unclear why repeated X-ray irradiation
but not repeated C-ion irradiation conferred significant C-ion-
resistance to NR-S1 derivative-cells, we believe that enrichment
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FIGURE 2 | Analysis of Rad51-foci formation in parental NR-S1 cells and radioresistant X60 and C30 cells. (A,B) Representative immunofluorescence images of
NR-S1, X60, and C30 cells irradiated with 10Gy of X-ray radiation (A) or 5Gy of C-ion radiation (B), as previously described (51, 56). At the indicated time after
irradiation, cells were fixed and labeled with anti-Rad51 antibodies (green) using standard procedures (34, 35). Nuclei were counterstained by Hoechest33342 (blue).
Scale bars, 10µm. (C,D) Histograms showing the average number of Rad51 foci per cell following X-ray (C) and C-ion (D) irradiation of NR-S1 (blue), X60 (red), and
C30 (green) cells. Data represent the mean ± standard deviation.
in CSCs might be a contributing factor. Indeed, it is widely
recognized that CSCs are more resistant to X-ray radiation
and anticancer drugs than more differentiated cancer cells.
Furthermore, as noted, several studies report that repeated X-
ray irradiation can increase the CSC fraction within a cancer cell
population (49, 50, 72–74). Conversely, Cui et al. (75) showed
that C-ion radiation could efficiently kill CSCs both in vitro
and in vivo. Therefore, it is conceivable that repeated X-ray
irradiation but not repeated C-ion irradiation could contribute
to enriching a radioresistant subpopulation with CSC-like
characteristics. However, there is one element in contradiction
to this hypothesis. Because most CSCs are in a G0 quiescent
state (45), the non-CSC subpopulation might proliferate faster;
therefore, if the primary factor in the acquisition of X-ray and C-
ion resistance is enrichment in CSCs, the level of radioresistance
of a growing X60 cell population, for example, could gradually
decrease over time, which was not observed (34, 35).
Collectively, these findings indicate that CSC enrichment and
other mechanisms, such as genetic alterations and mutations
(76), might jointly contribute to the acquisition of both X-ray and
C-ion resistance in cancer cells. Although further investigations
are required to elucidate these mechanisms, the current body
of evidence suggests that C-ion irradiation does not induce
radioresistance and can be used for the treatment of locally
recurrent tumors arising after primary CIRT.
EFFECTS OF IN VIVO REPEATED PHOTON
OR C-ion IRRADIATION
Numerous studies are focused on translating results obtained
with in vitro models of radioresistant cancer cells into clinical
practice. Therefore, it appears essential to determine whether
phenotypic changes resulting from repeated photon or particle
irradiation also occur in vivo. However, to the best of our
knowledge, the effects of in vivo repeated photon or particle
irradiation on the acquisition of radioresistance in cancer cells
has not been reported.
To address this question and examine whether the
characteristics of repeatedly irradiated tumors differ from
those of parental tumors, we recently established in vivo models
of regrown irradiated tumors (77). To this end, NR-S1-derived
tumors engrafted into C3H/He mice were irradiated with
single doses of γ-ray (30Gy) or C-ion (15Gy) radiation, which
have comparable effects on tumor growth. Two weeks after
irradiation, we harvested the irradiated tumors and transplanted
them into healthy mice, and 2 weeks later, the regrown tumors
were irradiated again, with this irradiation/regrowth/transplant
process repeated six times in total. The resulting repeatedly
irradiated tumors were exposed to total doses of 180Gy of
γ-ray radiation and 90Gy of C-ion radiation and denoted as
G180 and C90 in vivo regrown tumor models, respectively
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FIGURE 3 | Diagram describing the establishment of regrown tumor models through repeated γ-ray or C-ion irradiation. Mouse squamous cell carcinoma NR-S1 cells
were injected into the right hind leg of healthy C3H/He mice. Upon reaching ∼10mm in diameter, tumors derived from NR-S1 cells were irradiated with 30Gy of γ-ray
radiation or 15Gy of C-ion radiation and allowed to regrow for 2 weeks before transplant into the right hind leg of healthy mice. The irradiation/regrow/transplant
procedure was performed six times in total, resulting in regrown tumors exposed to total doses of 180Gy of γ-ray radiation and 90Gy of C-ion radiation, respectively.
The tumors were finally harvested for analysis 4 weeks after the final irradiation (77).
(Figure 3). We then examined differences in tumor-growth
potential, spontaneous metastasis from the primary site to the
lung surface, tumor-grafted mouse survival, and radiosensitivity
between non-irradiated NR-S1-derived tumors and G180 and
C90 tumors.
Notably, G180 tumors displayed drastically increased tumor-
growth rates and metastatic potential compared with those of
non-irradiated tumors, and mice grafted with G180 tumors
displayed significantly shorter survival than those grafted with
non-irradiated tumors. By contrast, the characteristics of the
C90 tumors remained comparable to those of non-irradiated
tumors. Importantly, X-ray and C-ion irradiation of G180 and
C90 tumors did not affect the relative tumor-growth rates,
spontaneous lung metastasis, and survival of tumor-grafted
mice as compared with non-irradiated tumors. Furthermore,
colony formation assays performed using cells isolated from
non-irradiated, G180, and C90 tumors showed that they all
added similar sensitivity to X-ray and C-ion radiation (77).
Moreover, compared with non-irradiated and C90 tumors, G180
tumors harbored numerous microvessels and expressed genes
associated with angiogenesis and metastasis, including VEGFA,
HIF1A, FN1, MMP2, MMP9, PAI1, and PLAU. Together, these
data indicated that, contrary to repeated in vitro irradiation,
repeated in vivo γ-ray and C-ion irradiation did not lead to
the acquisition of radioresistance in regrown tumors. However,
repeated photon irradiation but not particle irradiation appeared
to enhance tumor growth and metastasis, resulting in an
increased aggressiveness of regrown tumors.
These findings could suggest that repeated irradiation affects
the tumor microenvironment rather than the tumor itself or
its CSC subpopulation. Although our investigations could not
determine whether repeated photon irradiation enriched the
CSC subpopulation in regrown tumors, our data showed that
G180 tumor cells in suspension culture had a significantly higher
sphere-formation potential than their non-irradiated and C90
counterparts (77). Because CSCs are characterized by significant
resistance to cytotoxic agents, including radiation and anticancer
drugs, we believe that G180 tumors are likely enriched in
tumor-initiating cells (TICs) that differ from a typical CSC
subpopulation. To date, such phenomena have not been reported,
and further studies will be required to determine which cells
among cancer and stromal cells are mostly affected by repeated
in vivo irradiation and what mechanisms lead to increased
aggressiveness in repeatedly irradiated tumors.
Crucially, these findings also demonstrated that repeated
C-ion irradiation was far less prone to induce acquisition of
radioresistance and enhance tumor aggressiveness, as assessed
by tumor growth, metastatic potential, and prognosis of
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tumor-grafted mice. Although it remains necessary to ascertain
why C-ion radiation effectively suppressed tumor aggressiveness
and TIC or CSC subpopulations, we believe that the accumulated
evidence supports CIRT as a promising treatment for local
recurrent tumors.
RELATIONSHIP BETWEEN THE 4Rs OF
RADIOTHERAPY AND RADIORESISTANCE
ACQUISITION
Tumor shrinkage by fractionated radiotherapy has been
explained by the “4Rs” of radiotherapy, where each “R” represents
“Repair,” “Repopulation,” “Redistribution,” and “Reoxygenation”
(78). “Repair” denotes the difference in cell survival of tumor
cells and normal tissue between single or fractionated irradiation
at the same radiation dose (79) and is basically measured by
colony formation assay, followed by calculation of α and β values
using a linear-quadratic model to quantify the radiosensitivity
of each cell (80). “Repopulation” describes regeneration of
normal tissue, such as skin and mucosal tissue (81). This concept
relies on experimental results showing that the recovery of skin
and mucosal tissue occurs faster than regrowth of gross tumor
mass, and that each fractionation regime of radiotherapy can be
determined based on these differences. Because α and β values
and difference in recovery between tumor and normal tissue are
used for treatment planning of radiotherapy, they are recognized
as important therapeutic components. “Redistribution” indicates
synchronization of the cell cycle in cells exposed to radiation. The
tumor harbors multiple cell types exhibiting various cell cycle
phases (82). Upon treatment of the tumor with radiotherapy,
the relatively radiosensitive cell fractions, such as those in the
G2/M phase, will die first, whereas the relatively radioresistant
cell fractions, such as those in the G1 and S phases, will survive.
However, cells surviving the first round of irradiation will
enter a radiosensitive phase of the cell cycle during subsequent
rounds and eventually will subsequently be efficiently killed.
“Reoxygenation” describes changes in well-oxygenated areas
of an irradiated tumor (83). Partial oxygen pressure in the
peripheral tumor is higher than that in the center, because
nutrition and oxygen at the periphery is well-supplied by tumor
blood vessels (78). The partial oxygen pressure enhances the cell-
killing effect, because radiation-induced reactive oxygen species,
such as OH radical, initiated DNA breakage (84). Therefore,
well-oxygenated areas of a tumor (i.e., the periphery) are killed
first, followed by vascularization of the central tumor along
with tumor shrinkage. Repetition of this process enhances the
efficacy of radiotherapy. The 4Rs reasonably describe the process
of tumor shrinkage during radiotherapy and are useful for
recognizing tumor and environmental conditions the determine
radioresistance or radiosensitivity.
On the other hand, our previous results suggest the possibility
that use of the 4Rs might not be appropriate for planning
secondary radiotherapy. At the very least, using the same
definitions as those used to determine primary radiotherapy
might not be suitable for secondary radiotherapy. If the tumor
targeted for secondary radiotherapy has acquired radioresistance
via EMT, the total dose required to control the tumor should
be increased. This suggests that the α and β values of the
tumor cells and the dose fractionation used to prevent normal-
tissue complications should be changed. Therefore, this suggests
that “Repair” and “Repopulation” should be properly adjusted
in the planning of secondary radiotherapy. In cases where
primary radiotherapy fails to control tumor growth, followed
by tumor regrowth within the irradiation field, this suggests
that radioresistant cancer cells, such as CSCs, likely exist
in the target area. If these tumors are treated with another
round of irradiation, “Reoxygenation” might not be suitable for
interpreting tumor radiosensitivity, because the CSCs might be
in a quiescent state and capable of surviving within the hypoxic
area. In addition to the induction of the radioresistant cancer
cells, our data showed that repeated photon irradiation in vivo
promoted acquisition of a more aggressive phenotype in the
tumors. These characteristic changes do not fit the classical 4Rs of
radiotherapy. Although our results were obtained by experiments
using mouse cancer cell lines rather that human specimens,
and the results in vitro did not match those obtained in vivo,
they indicated that other hallmarks are required to interpret
possible radioresistant or aggressive fractions in target tumors
for planning secondary radiotherapy targeting regrown tumors.
Given that hypoxic areas are primary niches of CSCs (85), and the
tumor vasculature clearly changes after irradiation (86), imaging
techniques used to identify hypoxic areas and well-vascularized
areas in target tumors will likely be useful for planning secondary
radiotherapy. Indeed, drugs targeting hypoxic areas have been
developed (87, 88), and tumor blood vessels can be visualized by
contrast-enhanced magnetic resonance imaging (89).
WHAT ARE THE MAIN OPEN QUESTIONS
IN THE FIELD?
Although numerous studies show that repeated X-ray irradiation
can lead to increased radioresistance in various cancer cells, the
primary source of radioresistant cancer cells remains elusive.
Therefore, it is imperative to determine whether the selection
of inherently radioresistant cells or emergence of radioresistant
cells due to de novo genetic alterations is the primary cause of the
acquisition of radioresistance in order to prevent the appearance
of radioresistance and improve patient care. With the recent
development of genetic barcoding techniques (90–93), we can
now label a large number of cells within a given population.
Combined with high-throughput DNA sequencing, genetic
barcoding could be used to track and identify the type(s) of cells
that can survive and proliferate following repeated irradiation.
Although extensive efforts have been made to investigate
the mechanisms of acquisition of radioresistance in cancer cells
using in vitro models, the radiobiological effects of repeated
in vivo irradiation remain poorly understood. Tumors are
complex ecosystems comprising various cell types, including
cancer, stromal, and immune cells. Furthermore, the tumor
environment is partly heterogeneous, with hypoxic or nutrient-
deprived areas. In this regard, our in vivo data suggest that
changes in the tumormicroenvironment, including angiogenesis,
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might be critical for the prognosis of mice bearing regrown
tumors after repeated irradiation.
In addition to the limited amount of data available concerning
the effects of repeated in vivo irradiation, the differences between
photon and particle irradiation remain largely unknown. Indeed,
photon and particle radiation have distinct physical properties,
and their resulting biological effects might be very different. For
example, particle radiation produces a high density of reactive
oxygen species and clustered DNA damage along the particle-
beam track (94). Nevertheless, there is, to date, no sensible theory
linking the physical characteristics of radiation to their biological
effects, including high relative biological effectiveness in cell-
survival assays and suppression of metastasis both in vitro and
in vivo.
Answers to these questions would definitely promote the
understand of why repeated C-ion irradiation does not appear
to induce significant radioresistance in cancer cells, whereas
repeated X-ray irradiation leads to significant resistance to both
X-ray and C-ion radiation in NR-S1 cells. The identification
of potential targets to enhance or elicit radiosensitization could
facilitate the development of novel therapeutic strategies for the
treatment of radioresistant tumors and recurrent tumors after
primary radiotherapy.
CONCLUDING REMARKS
To date, few reports have been published describing the
acquisition of radioresistance in repeatedly irradiated tumor cells,
particularly after particle irradiation. A series of experiments
using models of tumors repeatedly irradiated with either photon
or particle radiation show that repeated in vitro irradiation with
relatively high doses of X-ray radiation can induce significant
resistance to both X-ray and C-ion radiation. By contrast,
repeated in vitro irradiation with relative biological effectiveness
doses of C-ion radiation does not contribute to the acquisition of
X-ray or C-ion resistance in tumor cells. Somewhat surprisingly,
repeated X-ray or C-ion irradiation of in vivo regrown tumor
models does not increase their radioresistance; however, repeated
photon irradiation but not C-ion irradiation increased tumor
aggressiveness. Because the evidence was limited to a single
tumor cell type, further studies are required to conclusively
determine the effects of repeated irradiation on the acquisition
of radioresistance in tumors.
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